North America

New Delhi, July 22: Hurt by lower lenalidomide sales and a provision related to semaglutide, the consolidated net profit of Dr Reddy’s Laboratories attributable to equity holders fell 68.7 per cent year-on-year to ₹443.5 crore in the…
Read More...